Regencell Bioscience Holdings Limited — Form 6-K Summary
Business Context and Reporting Period
The filing is a Form 6-K submitted by Regencell Bioscience Holdings Limited, a Cayman Islands company with principal executive offices in Hong Kong. It covers January 2024 and was filed on January 2, 2024. The filing reports changes to the company’s board of directors.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- Dr. Yi-Chung Chao resigned as a director for personal reasons, effective December 27, 2023.
- The company stated that Dr. Chao’s resignation was not related to disagreements concerning the company’s operations, policies, or practices.
- On December 28, 2023, the board appointed James Wai Hong Chung, the company’s Chief Operating Officer, as a director to fill the vacancy.
- Mr. Chung will continue serving as Chief Operating Officer and has no family relationship with the company’s other officers or directors.
- Under his offer letter, Mr. Chung will receive an annual director fee of HK$84,000 in cash, payable monthly, plus reimbursement of reasonable business expenses.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The principal unusual item is the board transition and the related director compensation arrangement. The detailed offer letter is filed as Exhibit 10.1.
Investor Verification Items
- Confirm the effective dates of Dr. Chao’s resignation and Mr. Chung’s appointment.
- Review Exhibit 10.1 for the complete terms of Mr. Chung’s offer letter and director compensation.
- Assess any implications of the Chief Operating Officer also serving as a director.
- Consult the company’s periodic financial filings for current operating results, cash resources, liabilities, and funding requirements, which are not disclosed in this Form 6-K.